A single digital platform will unite genetic data, medical records, and imaging scans from thousands of NHS patients with fatty liver disease, creating a unified resource for researchers and drug developers. Non-alcoholic fatty liver disease (NAFLD) affects a growing number of people, yet it is notoriously difficult to diagnose because it causes no symptoms until late stages. The only reliable method—a needle biopsy—is painful and carries risk of serious complications. No approved drugs exist for the advanced form, NASH, and doctors cannot predict which patients will progress to liver fibrosis or cancer. The core problem is fragmentation: genetic data, hospital records, prescription histories, and scan images sit in separate systems across the NHS, universities, and pharmaceutical companies, making it nearly impossible to spot patterns that could lead to new diagnostics or treatments. If the platform succeeds, it will give clinicians and drug companies a single place to ask questions such as: which genetic markers predict progression? Do certain prescription drugs slow fibrosis? Can a blood test replace the biopsy needle? The project does not itself develop a new drug or diagnostic test, but it builds the data infrastructure needed to discover them. For patients, the payoff could be earlier diagnosis, fewer painful biopsies, and eventually treatments for a disease that currently has none.
View original technical description
"We are doing research to improve the health of people who get a kind of chronic liver disease called Non-alcoholic fatty liver disease (NAFLD). Patients who develop NAFLD may go on to develop more serious form of liver disease called non-alcoholic steatohepatitis (NASH), which can result in liver fibrosis and liver cancer. Ultimately these patients may need a liver transplant. It is very difficult to diagnose this disease as the vast majority of liver disease is found when the disease is at later stages because it does not cause symptoms before this point. The only reliable diagnostic method is biopsy where liver tissue is obtained by inserting a needle into the patient, and the tissue is then assessed under a microscope. Liver biopsy has serious limitations: it can be painful and there is a risk of serious complications. Despite this disease becoming more common, there are no approved drugs as a treatment for NASH and there is no way to determine which patients will develop the more serious form of the disease. In medicine and research, a huge amount of data is now available. This data is often scattered in many different locations. Even within the NHS, it exists is in many different forms and locations. Data can be in the form of information about genes and genetics, medical records, information from tests or prescription data or imaging data from scans or x-rays. If we want to include information from researchers or from drug companies working on this disease, it becomes even more complicated. Our project will bring all these different forms of data together in one place which should make the task of being able to diagnose and treat this disease much easier. We have assembled a multi-disciplinary team consisting of clinicians, data scientists, pathologists, computer scientists and drug companies to work together to determine what information they would need in order to be able to find new treatments for this disease, what we need to do to be able to tell if treatments are working, how we can diagnose this disease. When treatments become available, we should be also to determine which patients will go on to develop the more serious form of the disease."
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know